Aptamer probes for Epigenetic Peptide Targets
Aptamer probes for Epigenetic Peptide Targets
批准号:
7909907
负责人:
Mark Patrick McPike
金额:
$19.56万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-07-05 至 2011-09-30
关键词:
AffinityAgeAgingAntibodiesAsthmaAutistic DisorderAutomationBacteriaBase SequenceBindingBinding ProteinsBiologyBiosensorBiotinBipolar DisorderBuffersCell surfaceChemistryChromatinChromosomesChronic DiseaseCommunitiesCountryDNADevelopmentDiagnosticDiseaseEnsureEnzymesEpigenetic ProcessEvolutionFeesGene ExpressionGene Expression RegulationGeneticHistonesIn VitroLengthLibrariesMalignant NeoplasmsMeasuresMental HealthMethodsMicroarray AnalysisModificationMonozygotic TwinningMonozygotic twinsMutationNeurotransmittersNucleic AcidsNucleic acid sequencingOrganismPathogenesisPeptidesPerformancePhasePlayPrecipitationProcessProteinsProtocols documentationRNA SequencesRandomizedReagentRecombinantsResearchResearch PersonnelRoleSchizophreniaScreening procedureSpecificityStructureSurface Plasmon ResonanceTemperatureTestingTherapeuticUnited States National Institutes of HealthUniversitiesaptamerbasecostcross reactivityenzyme activityepigenomicsgenetic regulatory proteinhigh throughput screeninghistone modificationhuman diseaseinterestmeetingsnext generationnovelpromoterpublic health relevancerepositoryreproductiveresearch studysingle moleculesynthetic constructtool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant):
Epigenetic aberrations underlie the pathogenesis of a number of human diseases that lack clear genetic alterations. For example, mental health diseases such as bipolar disorder and schizophrenia are associated with epigenetic changes in the promoters of enzymes that metabolize neurotransmitters. Other diseases in which epigenetic factors have been shown to play a role include cancer, autism, asthma and reproductive diseases. Gene expression differences in aging monozygotic twins suggest that epigenetic drift may be associated with chronic diseases that appear as we age. One of the most promising aspects of epigenomic research is that, unlike genetic aberrations, epigenetic aberrations are potentially reversible, by modulating the activities of the enzymes that stabilize or remodel specific chromatin states. In this project a set of epigenetic peptide and protein targets will be screened against libraries of nucleic acids using OrthoSystems new and highly successful approach, High Throughput Screening of Aptamers (HTSA), for discovery of DNA/RNA molecules that bind proteins with high affinity and specificity. HTSA aptamer hits will be investigated under standard experimental conditions for sensitivity, cross reactivity and robustness. In Phase II, aptamers that meet or exceed our performance standards will be made available to the re- search community through NIH reagent repositories (limited offering) or for a fee from OrthoSystems, Inc (full product line with attachment chemistry.) These aptamer products will serve as low cost, renewable, standar- dized affinity reagents for epigenomic research. This collaborative project will be led by OrthoSystems, Inc. with a subcontract to Syracuse University.
PUBLIC HEALTH RELEVANCE:
Epigenetic aberrations underlie the pathogenesis of mental health diseases, such as bipolar disorder and schizophrenia, by causing changes in the regulation of genes that produce enzymes to metabolize neuro transmitter molecules. Other diseases in which epigenetic factors play a role include cancer, autism, asthma and reproductive diseases, and may also be associated with chronic diseases that appear as we age. Many proteins are known to have critical roles in the manner in which DNA is packed tightly into chromo- somes or is available for expression of genes. This project will provide new and far more effective tools to measure the degree to which these proteins are modified. Unlike genetic aberrations, epigenetic changes are potentially reversible by modulating the activities of the enzymes that stabilize or remodel the packing of DNA in chromosomes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Proteomic Analysis of Blood Plasma using High Throughput Sequencers
-
批准号:10009883
-
项目类别:
-
资助金额:$94.07万
-
财政年份:2020
-
负责人:Mark Patrick McPike
-
依托单位:
Proteomic Analysis of Blood Plasma using High Throughput Sequencers
-
批准号:10250328
-
项目类别:
-
资助金额:$104.54万
-
财政年份:2020
-
负责人:Mark Patrick McPike
-
依托单位:
Microarray Chips for Rapid Detection of High Affinity Nucleic Acid Sequences.
-
批准号:7928521
-
项目类别:
-
资助金额:$16.32万
-
财政年份:2009
-
负责人:Mark Patrick McPike
-
依托单位:
Microarray Chips for Rapid Detection of High Affinity Nucleic Acid Sequences.
-
批准号:7482692
-
项目类别:
-
资助金额:$64.59万
-
财政年份:2006
-
负责人:Mark Patrick McPike
-
依托单位:
Microarray chips for rapid detection of high affinity nucleic acid sequences
-
批准号:7159145
-
项目类别:
-
资助金额:$11.25万
-
财政年份:2006
-
负责人:Mark Patrick McPike
-
依托单位:
Microarray Chips for Rapid Detection of High Affinity Nucleic Acid Sequences.
-
批准号:7618630
-
项目类别:
-
资助金额:$32.76万
-
财政年份:2006
-
负责人:Mark Patrick McPike
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: